Written by The Malignant Ascites Treatment Market was valued at USD 846.3 million in 2025 and is projected to reach USD 1.5 billion by 2035, growing at a CAGR of 5.9% during 2026–2035. Market expansion is being supported by the increasing incidence of cancer-related ascites, advancements in treatment approaches, and growing awareness among healthcare professionals.
Treatment options include paracentesis, intraperitoneal chemotherapy, diuretics, and surgical intervention. Paracentesis remains an important treatment approach for managing fluid accumulation, while advances in targeted therapies, immunotherapies, and minimally invasive procedures are contributing to the development of new treatment strategies.
The market is segmented by treatment type, cause of ascites, administration route, patient demographics, and region. Treatment routes include intravenous, oral, and intraperitoneal administration, while adults and geriatric patients represent key demographic segments. Hospitals and specialized healthcare facilities remain important settings for diagnosis and treatment.
North America is projected to maintain a significant market position, supported by advanced healthcare infrastructure and cancer-care investment. Asia Pacific is expected to experience substantial expansion as healthcare access, cancer awareness, and medical infrastructure improve. Continued research into personalized treatment approaches and novel therapies is expected to create further opportunities in the market.